Denali Capital Acquisition entered into a PIPE agreement with FutureTech Capital, which agreed to buy 1.8 million shares at $10 each.
The financing is in support of the SPAC’s planned merger with Longevity Biomedical, which is focused on advancing new technologies across therapeutics, health monitoring and digital health solutions “to increase human health span.”
As announced in January, the deal has a pro forma equity valuation of approximately $236.2 million, which assumes zero redemptions.
The SPAC has an Oct. 11 completion deadline. Read more.
